The study, published Aug. 18 in The New England Journal of Medicine, was funded by the National Institutes of Health and the Biomedical Advanced Research and Development Authority, an HHS office that develops responses to health security threats. It included 511 patients with a median age of 54.
“We were hoping that the use of COVID-19 convalescent plasma would achieve at least a 10% reduction in disease progression in this group, but instead the reduction we observed was less than 2%,” Clifton Callaway, MD, principal investigator for the study and professor of emergency medicine at the University of Pittsburgh, said in a news release.
The clinical trial was halted in February after an independent board concluded convalescent plasma was unlikely to help high-risk patients in emergency rooms.
Find the full study results here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
